Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
FDA Okays Subcutaneous Ocrelizumab for MS
The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of the anti-CD20 antibody ocrelizumab (Ocrevus Zunovo, Genentech) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The subcutaneous (SC) injection can be…
English